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With the event of trans-catheter aortic-valve implanta-
tion, the left-ventricular trans-apical access has gained
renewed interest. While most studies report very few
access-related complications, one recent study reports
bleeding in 5% and formation of late pseudo-aneurysms in
6.6% of cases [1]. In rare cases (small ventricle, fragile
tissue), rupture of the left-ventricular apex can occur and
eventually lead to a fatal outcome [2]. It is therefore of
interest to explore alternative direct cardiac access sites for
aortic-valve implantation. The subxyphoid approach has
been successfully used for single-port epicardial ablation of
atrial fibrillation, and transabdominal, transdiaphragmatic
endoscopic bypass grafting has been explored in an
experimental setting [3].
In this issue, Liu et al. present a new method for
subxyphoidal right-ventricular access for transseptal aor-
tic-valve implantation [4]. While the authors have to be
congratulated for their continuing and pioneering effort in
developing devices to facilitate trans-apical aortic-valve
implantation, this approach seems a little bit circumstan-
tial. It is argued that opening the pleura can be avoided
using a subxyphoidal approach and that general anesthesia
may therefore no longer be needed. The requirement of
general anesthesia for trans-apical aortic-valve implanta-
tion is continuously brought forward as a disadvantage
when compared with the transfemoral access, which is now
more often performed in local anesthesia. However, it has
already been demonstrated that standard trans-apical
aortic-valve implantation through the 5th or 6th left
intercostal space can also be performed in the awake,
spontaneously breathing patient using high epidural
analgesia and despite pleural opening. However, there
are other good reasons to favor general anesthesia in the
setting of trans-catheter valve implantation. First, severe
and life-threatening complications requiring cardiopul-
monary bypass or cardiopulmonary resuscitation (CPR) can
occur during the procedure at anytime. This can be
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Second, uncontrolled motion of the patient during valve
deployment can unarguably lead to valve dislocation, a
problem that can easily be avoided if the patient is asleep.
Not general anesthesia itself, but prolonged ventilation is
disadvantageous for the patient. Trans-catheter valve
implantation should therefore go in hand with a fast-track
anesthesia concept, applying short-acting anesthetics and
early extubation.
The creation of an iatrogenic ventricular septal defect
(VSD) is required for the proposed access. While this was
successfully treated with the application of an Amplatzer
occluder, the reasonableness of means can be put to
question. Percutaneous closure of a VSD is associated with
a relatively high risk of both peri-interventional and
potential long-term complications. These include, but are
not limited to, incomplete closure with residual shunt, the
risk of device embolisation and migration, thrombo-
embolic complications (pulmonary and systemic), hemo-
lysis, arrhythmias and the risks associated with the need
for anticoagulation are added to the procedure. Trans-
catheter valve implantation is already expensive; the
addition of devices to treat access-related collateral
damage would further increase the economic burden.
For cases in whom standard aortic-valve replacement is
truly not an option and neither the transfemoral, transsub-
clavian nor the trans-apical approach is feasible, a direct
trans-aortic approach may be useful [5]. We must also accept
that, even in 2010, some patients may be served best with no
intervention at all.
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